Volume 15, Issue 1 (Winter 2026)
aumj 2026, 15(1): 94-102 |
Back to browse issues page
Ethics code: IR.UMSU.REC.1398. 327.
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mansouri F. Investigation of miRNAs and mRNAs in mesenchymal stem cells for cardiovascular diseases. aumj 2026; 15 (1) :94-102
URL: http://aums.abzums.ac.ir/article-1-1934-en.html
URL: http://aums.abzums.ac.ir/article-1-1934-en.html
Department of Genetics and Immunology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran & Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran , mansouri1600@hotmail.com
Abstract: (334 Views)
Introduction: The prevalence of cardiovascular disease is increasing with the age and the increase in the world's population. Cellular, molecular and physiological changes in the heart and blood vessels can improve heart diseases. Investigating the precise molecular pathogenesis pathways of heart disease can lead to early diagnosis and effective treatment for the disease. Accurate diagnostic biomarkers are very valuable and effective for clinical applications. The present study was conducted to find miRNAs and their target genes.
Methods: The miRNAs and their gene targets in the disease were determined from the GEO and miRDB databases by statistical analysis of p<0.01 and logFC#1. MiRNAs with the most expression changes in angiogenesis were selected. ROC curve analysis for sensitivity and specificity of miRNAs was performed in XLSTAT software version 2016. Ethics Code in Iran IR.UMSU.REC.1398. 327.
Results: The results of statistical analysis showed that 370 miRNAs have different expression. Of these, 180 miRNAs increased in expression, 120 miRNAs decreased in expression, and the others showed no significant change. Analysis of molecular pathways revealed that some of these miRNAs are involved in various processes including angiogenesis, hypoxia, and apoptosis. It was also found that miR-665, miR-216a-5p and miR-34a are important in angiogenesis. For these miRNAs, the ROC analysis determined the area under the curve to be 0.86 with a specificity of 0.89 and a sensitivity of 0.87.
Conclusion: Identification of miRNA changes and the targets of involved genes can increase the therapeutic effects of stem cells and be considered an effective method in the treatment of cardiovascular diseases.
Methods: The miRNAs and their gene targets in the disease were determined from the GEO and miRDB databases by statistical analysis of p<0.01 and logFC#1. MiRNAs with the most expression changes in angiogenesis were selected. ROC curve analysis for sensitivity and specificity of miRNAs was performed in XLSTAT software version 2016. Ethics Code in Iran IR.UMSU.REC.1398. 327.
Results: The results of statistical analysis showed that 370 miRNAs have different expression. Of these, 180 miRNAs increased in expression, 120 miRNAs decreased in expression, and the others showed no significant change. Analysis of molecular pathways revealed that some of these miRNAs are involved in various processes including angiogenesis, hypoxia, and apoptosis. It was also found that miR-665, miR-216a-5p and miR-34a are important in angiogenesis. For these miRNAs, the ROC analysis determined the area under the curve to be 0.86 with a specificity of 0.89 and a sensitivity of 0.87.
Conclusion: Identification of miRNA changes and the targets of involved genes can increase the therapeutic effects of stem cells and be considered an effective method in the treatment of cardiovascular diseases.
Type of Study: Original |
Subject:
Special
Received: 2025/08/10 | Accepted: 2026/01/28 | Published: 2026/02/21
Received: 2025/08/10 | Accepted: 2026/01/28 | Published: 2026/02/21
References
1. Hua CC, Liu XM, Liang LR, Wang LF, Zhong JC. Targeting the microRNA-34a as a Novel Therapeutic Strategy for Cardiovascular Diseases. Frontiers in cardiovascular medicine. 2021;8:784044. [DOI:10.3389/fcvm.2021.784044]
2. Chhotaray S, Jal S. Identifying Biomarkers for Atherosclerosis via Gene Expression and Biological Networking. Current cardiology reviews. 2025. [DOI:10.2174/011573403X340118241113025519]
3. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149(8):e347-e913. [DOI:10.1161/CIR.0000000000001247]
4. Mansouri F, Seyed Mohammadzad MH. Decreased Expression of Cytotoxic T Lymphocyte-associated Protein 4: A Risk Factor of Myocardial Infarction. Iranian journal of allergy, asthma, and immunology. 2022;21(1):86-91. [DOI:10.18502/ijaai.v21i1.8621]
5. Yaghoobi A, Rezaee M, Behnoush AH, Khalaji A, Mafi A, Houjaghan AK, et al. Role of long noncoding RNAs in pathological cardiac remodeling after myocardial infarction: An emerging insight into molecular mechanisms and therapeutic potential. Biomedicine & Pharmacotherapy. 2024;172:116248. [DOI:10.1016/j.biopha.2024.116248]
6. Nappi F. Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review. International journal of molecular sciences. 2024;25(7). [DOI:10.3390/ijms25073630]
7. Gholikhani-Darbroud R, Khaki-Khatibi F, Mansouri F, Hajahmadipoorrafsanjani M, Ghojazadeh M. Decreased circulatory microRNA-4478 as a specific biomarker for diagnosing non-ST-segment elevation myocardial infarction (NSTEMI) and its association with soluble leptin receptor. Bratisl Lek Listy. 2017;118(11):684-90. [DOI:10.4149/BLL_2017_129]
8. Rotllan N, Price N, Pati P, Goedeke L, Fernández-Hernando C. microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis. 2016;246:352-60. [DOI:10.1016/j.atherosclerosis.2016.01.025]
9. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336-42. [DOI:10.1038/nature09783]
10. Tesauro M, Schinzari F, Rovella V, Melina D, Mores N, Barini A, et al. Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes care. 2008;31(7):1439-41. [DOI:10.2337/dc08-0219]
11. Mansouri F. Use of Stem Cell-derived Exosomes as a Therapeutic Approach in Cardiovascular Disease in Personalized Medicine. Alborz University Medical Journal. 2021;10(3):337-43.
12. Mansouri F. A Review of Stem Cell Technology. Alborz University Medical Journal. 2018;7(3):181-9. [DOI:10.29252/aums.7.3.181]
13. Luxán G, Dimmeler S. The vasculature: a therapeutic target in heart failure? Cardiovascular research. 2022;118(1):53-64. [DOI:10.1093/cvr/cvab047]
14. Ilieva M, Panella R, Uchida S. MicroRNAs in Cancer and Cardiovascular Disease. Cells. 2022;11(22). [DOI:10.3390/cells11223551]
15. Mansouri F, Seyed Mohammadzad MH. Molecular miR-19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis. Asian Pac J Cancer Prev. 2020;21(4):975-82. [DOI:10.31557/APJCP.2020.21.4.975]
16. Xiao Y, Zhao J, Tuazon JP, Borlongan CV, Yu G. MicroRNA-133a and Myocardial Infarction. Cell transplantation. 2019;28(7):831-8. [DOI:10.1177/0963689719843806]
17. Mansouri F, Seyed Mohammadzad Mh. Bioinformatics analyses of potential microRNAs and their target genes in myocardial infarction patients with diabetes. Diabetes & Vascular Disease Research. 2025;22(3):14791641251335925. [DOI:10.1177/14791641251335925]
18. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic acids research. 2011;39(Database issue):D152-7. [DOI:10.1093/nar/gkq1027]
19. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550-9. [DOI:10.1161/CIRCULATIONAHA.114.009625]
20. Yang X, Cheng K, Wang LY, Jiang JG. The role of endothelial cell in cardiac hypertrophy: Focusing on angiogenesis and intercellular crosstalk. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023;163:114799. [DOI:10.1016/j.biopha.2023.114799]
21. Cooke JP. NO and angiogenesis. Atherosclerosis Supplements. 2003;4(4):53-60. [DOI:10.1016/S1567-5688(03)00034-5]
22. Kassan M, Vikram A, Kim YR, Li Q, Kassan A, Patel HH, et al. Sirtuin1 protects endothelial Caveolin-1 expression and preserves endothelial function via suppressing miR-204 and endoplasmic reticulum stress. Scientific reports. 2017;7:42265. [DOI:10.1038/srep42265]
23. Li Y, Yan C, Fan J, Hou Z, Han Y. MiR-221-3p targets Hif-1α to inhibit angiogenesis in heart failure. Laboratory investigation; a journal of technical methods and pathology. 2021;101(1):104-15. [DOI:10.1038/s41374-020-0450-3]
24. Juni RP, Kocken JMM, Abreu RC, Ottaviani L, Davalan T, Duygu B, et al. MicroRNA-216a is essential for cardiac angiogenesis. Molecular therapy : the journal of the American Society of Gene Therapy. 2023;31(6):1807-28. [DOI:10.1016/j.ymthe.2023.04.007]
25. Vonhögen IGC, Mohseni Z, Winkens B, Xiao K, Thum T, Calore M, et al. Circulating miR-216a as a biomarker of metabolic alterations and obesity in women. Non-coding RNA research. 2020;5(3):144-52. [DOI:10.1016/j.ncrna.2020.08.001]
26. Reddy S, Hu DQ, Zhao M, Ichimura S, Barnes EA, Cornfield DN, et al. MicroRNA-34a-Dependent Attenuation of Angiogenesis in Right Ventricular Failure. Journal of the American Heart Association. 2024;13(3):e029427. [DOI:10.1161/JAHA.123.029427]
27. Yu Y, Tian T, Tan S, Wu P, Guo Y, Li M, et al. MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. Bioengineered. 2022;13(2):2927-42. [DOI:10.1080/21655979.2021.2017698]
28. Fan J, Li H, Nie X, Yin Z, Zhao Y, Zhang X, et al. MiR-665 aggravates heart failure via suppressing CD34-mediated coronary microvessel angiogenesis. Aging. 2018;10(9):2459-79. [DOI:10.18632/aging.101562]
29. Gaddam RR, Kim YR, Jacobs JS, Yoon JY, Li Q, Cai A, et al. The microRNA-204-5p inhibits APJ signalling and confers resistance to cardiac hypertrophy and dysfunction. Clinical and translational medicine. 2022;12(1):e693. [DOI:10.1002/ctm2.693]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
